Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article (0)
Advertisement

ResearchIn-Press PreviewImmunology Open Access | 10.1172/jci.insight.183676

BLIMP-1 and CEACAM1 cooperatively regulate human Treg homeostasis and function to control xenogeneic GVHD

Ying Ding,1 Aixin Yu,1 Milos Vujanac,1 Sabrina N. Copsel,1 Alejandro Moro,1 Luis Nivelo,1 Molly Dalzell,1 Nicolas Tchitchek,2 Michelle Rosenzwajg,2 Alejandro V. Villarino,1 Robert B. Levy,1 David Klatzmann,2 and Thomas R. Malek1

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Ding, Y. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Yu, A. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Vujanac, M. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Copsel, S. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Moro, A. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Nivelo, L. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Dalzell, M. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Tchitchek, N. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Rosenzwajg, M. in: PubMed | Google Scholar |

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Villarino, A. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Levy, R. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Klatzmann, D. in: PubMed | Google Scholar |

1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America

2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France

Find articles by Malek, T. in: PubMed | Google Scholar

Published August 7, 2025 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.183676.
Copyright © 2025, Ding et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published August 7, 2025 - Version history
View PDF
Abstract

Regulatory T cells (Tregs) are essential for peripheral tolerance and depend on TCR and IL-2R signaling for their homeostasis and function. In mice, IL-2-dependent BLIMP-1 contributes to Treg homeostasis. BLIMP-1 is a major transcriptional hub in human Tregs, but its mechanisms of action remain undefined. Here, using CRISPR/Cas9 ablation, we show that BLIMP-1 limits human Treg proliferation, but supports IL-10, CTLA4, several immune checkpoints, including CEACAM1, and Treg functional activity. BLIMP-1 restrains Treg expansion to IL-2 by downregulating CD25 and IL-2R signaling, and by enhancing CEACAM1 expression, which in turn inhibits responsiveness to CD3/CD28 signaling and activation of mTOR. Prolonged IL-2R signaling optimizes BLIMP-1 expression, supporting chromosomal opening of CEACAM1 to increased CEACAM1 expression through STAT5- and BLIMP-1-driven enhancers. Correspondingly, CEACAM1 is highly induced on Tregs from autoimmune patients undergoing low-dose IL-2 therapy, and these Tregs showed reduced proliferation. A humanized mouse model of xenogeneic graft versus host disease demonstrates that BLIMP-1 normally promotes, while CEACAM1 restrains, Treg suppressive activity. Collectively, our findings reveal that BLIMP-1 and CEACAM1 function in an IL-2-dependent feedback loop to restrain Treg proliferation and affect suppressive function. CEACAM1 also acts as a highly selective biomarker of IL-2R signaling in human T cells.

Graphical Abstract
graphical abstract
Supplemental material

View Unedited blot and gel images

View This file includes all supplemental figures and table with legends.

View

Version history
  • Version 1 (August 7, 2025): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (0)

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts